TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study

Lenercept Multiple Sclerosis Study Group and The … - Neurology, 1999 - AAN Enterprises
Objective: A double-blind, placebo-controlled phase II study was conducted in 168 patients,
most with relapsing-remitting MS, to evaluate whether lenercept would reduce new lesions
on MRI. Background: Tumor necrosis factor (TNF) has been implicated in MS pathogenesis,
has been identified in active MS lesions, is toxic to oligodendrocytes in vitro, and worsens
the severity of experimental allergic encephalomyelitis (EAE) in animals. Lenercept, a
recombinant TNF receptor p55 immunoglobulin fusion protein (sTNFR-IgG p55), protects …

[CITATION][C] TNF neutralization in MS-Results of a randomized, placebo-controlled multicenter study

B Arnason, G Jacobs, M Hanlon, B Clay, A Noronha… - Neurology, 1999 - ora.ox.ac.uk
TNF neutralization in MS - Results of a randomized, placebo-controlled multicenter study - ORA
- Oxford University Research Archive Logos Header links Search History Bookmarks 0 New
Search Collections About Deposit Help Footer links Policies Disclaimer Privacy Policy Cookies
Accessibility Statement Copyright API Contact Skip to main NEW SEARCH Collections About
Deposit HELP 0 Back to Search CONTACT Name Email Comment Send message Actions
Authors Bibliographic Details Item Description Terms of Use Metrics Export BibTeX EndNote …